BioPorto Diagnostics is proud to announce that we have established a prominent European Scientific Advisory Board, and we will host the first meeting in Brussels May 2014 with next meeting planned in the Autumn of 2014. We have received acceptance from a group of renowned and leading acute kidney injury (AKI) specialists from cardiac, nephrology and ICU medical areas. Our Board members will challenge current published knowledge and by applying their experience and expertise, the goal is to move current knowledge to a higher level. Ultimately, the aim will be to identify and set forth sound clinical practical approaches that will lead the way for improvements of AKI diagnostics.
The Scientific Advisory Board members are:
Prof. Dr. med Jean-Louis Vincent, Erasme, Belgium. (Chair)
- Assoc. Prof. Dr. med Andrew Lewington, St. James’s University Hospital, Leeds, UK. (Vice Chair)
- Director Dr. med Claudio Ronco, San Bortolo Hospital, Vicenza, Italy
- Prof. Dr. med Laurent Jacob, Saint-Louis Hospital, Paris, France
- Prof. Dr. med Michael Haase, Otto-von.Guericke University, Magdeburg, Germany
- Dr. med, PhD, Hilde RH DE Geus, Eramus University Medical Center Rotterdam, NL
Acute kidney injury is a syndrome that affects patients across several medical and surgical specialties, and is a syndrome with poor outcome. The Scientific Advisory Board meetings will address the challenges and unmet needs for AKI diagnostics within a specific medical area at bi-annual meetings.
Meetings in 2014 will address AKI and neutrophil gelatinase-associated lipocalin (NGAL) biomarker challenges and opportunities within two major surgical specialties: Kidney Transplantation and Cardiopulmonary Bypass (CPB) procedures.
For questions or comments, please contact CEO Peter M. Eriksen or Marketing Manager Thomas Lowes
Tel.: +45 4529 0000
About BioPorto Diagnostics A/S
BioPorto Diagnostics A/S is an in-vitro diagnostics company that provides healthcare professionals in clinical and research settings a range of diagnostic tests and antibodies. Our pioneering product portfolio includes assays for underserved disease states such as NGAL for acute kidney injury. We sell our products in more than 80 countries through diverse sales channels and partners. BioPorto has its headquarters in Copenhagen, Denmark and is listed on the NASDAQ OMX: BIOPOR Copenhagen stock exchange.
